Vanqua Bio
Vanqua Bio is a Chicago-based clinical-stage biopharmaceutical company developing oral small-molecule therapies for neurodegenerative diseases, including GCase activators for Parkinson's (GBA-PD) and C5aR1 antagonists for neuroinflammation, monetized through licensing and milestone deals.
- Company typePrivate
- Founded2019
- HeadquartersChicago, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vanqua Bio does
Vanqua Bio is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Chicago, IL. The company discovers and develops small-molecule therapies for neurodegenerative and neuroinflammatory diseases, with its primary focus on genetically defined forms of Parkinson's disease (GBA-PD), Dementia with Lewy Bodies, and Gaucher disease. Its lead asset, VQ-101, is an oral, brain-penetrant allosteric activator of glucocerebrosidase (GCase) designed to restore lysosomal function in neurons carrying GBA1 mutations. The pipeline also includes C5aR1 antagonist compounds targeting complement-mediated neuroinflammation in CNS and peripheral indications.
Vanqua's drug discovery platform is built on patient-derived induced pluripotent stem cell (iPSC) neuronal models, grounded in the academic work of scientific founder Dimitri Krainc at Northwestern University. This platform supports target validation and lead optimization in disease-relevant human cell types. VQ-101 has progressed into Phase 1b clinical evaluation, with positive interim data reported in late 2025.
The company operates a licensing- and milestone-driven business model rather than a commercial one. It has no approved products and no product revenue; capital is sourced from private equity financing rounds led by healthcare-focused institutional investors, and non-dilutive capital is generated through partnership transactions — most notably the October 2025 license of its C5aR1 antagonist program to Biogen for $70M upfront and up to $990M in potential milestones.
Vanqua Bio firmographics
Firmographics- Name
- Vanqua Bio
- Legal name
- Vanqua Bio, Inc.
- Website
- https://vanquabio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vanqua Bio is a Chicago-based clinical-stage biopharmaceutical company developing oral small-molecule therapies for neurodegenerative diseases, including GCase activators for Parkinson's (GBA-PD) and C5aR1 antagonists for neuroinflammation, monetized through licensing and milestone deals.
- Ownership category
- akta.pro rank
Vanqua Bio industry classification
Industry- Product category
- Biopharmaceuticals — Neurodegenerative Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Vanqua Bio is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vanqua Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Licensing and Milestone Revenue: Pre-revenue clinical-stage biotech company. Generating revenue through licensing deals with pharmaceutical partners. In October 2025, Vanqua Bio received $70 million upfront payment from Biogen for licensing exclusive worldwide rights to its preclinical oral C5aR1 antagonist, with potential additional milestone payments of up to $990 million.
- Future Product Revenue: Once clinical candidates receive regulatory approval, the company will pursue commercialization of novel therapeutics for neurodegenerative diseases, targeting Parkinson's disease, Dementia with Lewy Bodies, and other neurological disorders.
Go-to-market motion1 record
Marketing channels4 records
Vanqua Bio product offering
Product offeringCore offering
Vanqua Bio is a clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for neurodegenerative diseases, anchored by VQ-101, an oral, brain-penetrant allosteric activator of glucocerebrosidase (GCase) in Phase 1b development for GBA-Parkinson's disease and related disorders. The company also develops C5aR1 antagonists targeting complement-mediated inflammation, with the peripheral program (VQ-201) licensed to Biogen and CNS-penetrant C5aR1 candidates retained for neuroinflammation. Discovery is enabled by a proprietary patient iPSC-derived neuronal cell screening platform combined with allosteric activator chemistry.
Product overview
Vanqua Bio is a clinical-stage biopharmaceutical company with two core therapeutic programs: VQ-101, an oral brain-penetrant allosteric activator of GCase currently in Phase 1b clinical trials for Parkinson's disease, and a C5aR1 antagonist program (including VQ-201 for peripheral indications and CNS-penetrant candidates) that was licensed to Biogen in 2025. The company's discovery platform utilizes patient-derived iPSC neurons to identify novel small-molecule therapies targeting lysosomal dysfunction and innate immune system overactivation in neurodegenerative and inflammatory diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- VQ-101 An orally administered, fully brain-penetrant small-molecule allosteric activator of glucocerebrosidase (GCase) for the treatment of GBA-Parkinson's disease, idiopathic Parkinson's disease, Dementia with Lewy Bodies, and all forms of Gaucher disease. Designed to restore GCase activity to healthy levels and block accumulation of pathological alpha-synuclein. First small molecule to demonstrate >75% activation of lysosomal GCase in humans, with full CNS penetrance (CSF:unbound plasma ratios ≥1) and projected once-daily oral dosing.
- VQ-201 A next-generation allosteric small-molecule C5aR1 antagonist targeting complement-mediated inflammation for peripheral inflammatory disorders. Demonstrated robust blockade of C5a-mediated chemotaxis and activation of pathogenic immune cells, with renal protection in preclinical models. Licensed to Biogen in October 2025 for exclusive worldwide development and commercialization rights.
- CNS-penetrant C5aR1 antagonist program First-in-class CNS-penetrant C5aR1 antagonists targeting neuroinflammation in central nervous system disorders, including Alzheimer's disease. Designed to reduce pathogenic complement-mediated activation of CNS immune cells and slow disease progression. Retained by Vanqua Bio as part of its CNS-focused pipeline following the Biogen licensing of the peripheral C5aR1 program.
Companies that use Vanqua Bio
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Vanqua Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Vanqua Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Biogen Inc.coreVanqua Bio entered an exclusive worldwide licensing agreement with Biogen for Vanqua's preclinical oral C5aR1 antagonist program. Biogen received rights to develop and commercialize the peripherally-directed compound for inflammatory diseases. Vanqua received $70 million upfront payment and is eligible for up to $990 million in development, regulatory, commercial, and sales milestone payments, plus tiered royalties on potential net sales. Biogen plans to advance the program into clinical development with an IND filing expected in 2027. This deal marks Biogen's first pipeline acquisition in 2025 and strengthens their immunology portfolio.
- Centre for Human Drug Research (CHDR)coreClinical research organization in the Netherlands conducting Vanqua Bio's Phase 1 clinical trial of VQ-101. The Phase 1a portion was conducted at CHDR facilities, evaluating safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.
- Northwestern University / Krainc LaboratorycoreFoundational research partner. Technology platform based on seminal research by Dimitri Krainc, MD, PhD, Chair of Neurology at Northwestern University's Feinberg School of Medicine. Dr. Krainc chairs Vanqua Bio's Scientific Advisory Board and is a co-founder. Company founded in proximity to Northwestern's world-renowned Krainc Laboratory.
Scale indicators5 records
Expansion highlights5 records
Vanqua Bio competitors and assessment
Company assessmentEmerging players
- Voyager Therapeutics: Gene therapy biotech targeting CNS diseases including Parkinson's. Comparable neuroscience focus and disease-modifying thesis but uses AAV gene therapy rather than Vanqua Bio's small-molecule approach.
- Prothena Corporation: Late-stage clinical biotech targeting alpha-synuclein for Parkinson's disease. Pursues a different therapeutic modality (antibodies) but addresses the same synucleinopathy pathology underlying Vanqua Bio's GCase activator mechanism.
- Cerevel Therapeutics: CNS-focused clinical-stage biotech developing small molecules for neuroscience indications including Parkinson's. Comparable in stage, modality, and CNS small-molecule discovery, though broader in therapeutic area than Vanqua Bio.
- Yumanity Therapeutics: Clinical-stage biotech developing disease-modifying therapies for Parkinson's and related neurodegenerative diseases. Comparable in disease focus and stage but pursued protein-misfolding-based targets rather than GCase activation.
- Lexeo Therapeutics: Clinical-stage gene therapy biotech with CNS programs including for GBA-Parkinson's. Comparable in stage and GBA1 disease focus, applying AAV gene therapy as an alternative modality to Vanqua Bio's small-molecule activators.
Direct peers
- Denali Therapeutics: Clinical-stage biotech developing small-molecule therapies for neurodegenerative diseases including Parkinson's and lysosomal storage disorders. Directly comparable to Vanqua Bio given shared GBA-PD focus, CNS-penetrant small-molecule strategy, and patient-derived iPSC discovery approach.
- Alector: Clinical-stage neurodegeneration biotech with programs targeting lysosomal function and neuroinflammation for Parkinson's and Alzheimer's. Comparable business model, stage, and neurodegenerative focus; both companies emerged from elite academic neuroscience labs with similar financing syndicates.
- Prevail Therapeutics (Eli Lilly): Acquired by Eli Lilly in 2020 to develop AAV gene therapies for Parkinson's and other CNS disorders, including a GBA1 program. Most direct GBA-PD peer; contrasts with Vanqua Bio's small-molecule allosteric activator approach.
- Sage Therapeutics: Clinical-stage CNS biopharma developing brain-penetrant small molecules for neurological disorders. Comparable in stage, CNS small-molecule discovery approach, and partnership-driven business model (e.g., Zurzuvae collaboration with Biogen).
- Edgewise Therapeutics: Clinical-stage muscle and CNS biotech; CSO Kevin Hunt previously served as Executive Director of Drug Discovery at Edgewise. Comparable in stage, therapeutic modality (small molecules), and CNS focus area.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Vanqua Bio social profiles
Digital presenceVanqua Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vanqua Bio leadership team
Management profileNumber of profiles
Profiles12 records
Vanqua Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vanqua Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vanqua Bio
What does Vanqua Bio do?
Vanqua Bio is a clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for neurodegenerative diseases, anchored by VQ-101, an oral, brain-penetrant allosteric activator of glucocerebrosidase (GCase) in Phase 1b development for GBA-Parkinson's disease and related disorders. The company also develops C5aR1 antagonists targeting complement-mediated inflammation, with the peripheral program (VQ-201) licensed to Biogen and CNS-penetrant C5aR1 candidates retained for neuroinflammation. Discovery is enabled by a proprietary patient iPSC-derived neuronal cell screening platform combined with allosteric activator chemistry.
Is Vanqua Bio a public or private company?
Vanqua Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vanqua Bio founded?
Vanqua Bio was founded in 2019. It employs 11 to 50 people.
Where is Vanqua Bio based?
Vanqua Bio is headquartered in Chicago, United States, in the North America region.
How does Vanqua Bio make money?
Two revenue lines are on record. Licensing and Milestone Revenue is the primary driver. The others are future Product Revenue.
Who are Vanqua Bio's main competitors?
Emerging players on record are Voyager Therapeutics, Prothena Corporation, Cerevel Therapeutics, Yumanity Therapeutics and Lexeo Therapeutics. Direct peers are Denali Therapeutics, Alector, Prevail Therapeutics (Eli Lilly), Sage Therapeutics and Edgewise Therapeutics.
Does Vanqua Bio have an API?
No public API is recorded for Vanqua Bio.
What industry is Vanqua Bio in?
Vanqua Bio's product category is Biopharmaceuticals — Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.